NASDAQ:BCDA

Biocardia Stock Insider Trading

Healthcare > Biotechnology

Buy BCDA

*Your capital is at risk

$0.87

-0.0256 (-2.84%)

At Close: Jun 03, 2026

BioCardia Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 5.34M and sold 0 BCDA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	5.34M shares
● Sell	0 shares
100% Buy Activity Moderate Negative Correlation
Buy Signal High Confidence Feb 23, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 100. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (100% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 14, 2025 Buy	Common Stock P-Purchase	Altman Peter President And CEO	CEO / President	100 Value: $299
Apr 23, 2025 Buy	Common Stock P-Purchase	Krasno Richard M Director	Director	13 123 Value: $25.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Krasno Richard M Director	Director	13 123 Value: $25.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Krasno Richard M Director	Director	13 123 Value: $25.0K
Apr 23, 2025 Buy	Common Stock P-Purchase	Krasno Richard M Director	Director	13 123 Value: $25.0K
Apr 23, 2025 Buy	Common Stock P-Purchase	Mcclung David Chief Financial Officer	C-Suite Officer	13 123 Value: $25.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Mcclung David Chief Financial Officer	C-Suite Officer	13 123 Value: $25.0K
Apr 23, 2025 Buy	Common Stock P-Purchase	Facteau Bill Director	Director	13 123 Value: $25.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Facteau Bill Director	Director	13 123 Value: $25.0K
Apr 23, 2025 Buy	Common Stock P-Purchase	Blank Andrew Scott Director	Director	131 233 Value: $250.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Blank Andrew Scott Director	Director	131 233 Value: $250.0K
Apr 23, 2025 Buy	Common Stock P-Purchase	Stertzer Simon H Director	Director	104 986 Value: $200.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Stertzer Simon H Director	Director	104 986 Value: $200.0K
Apr 23, 2025 Buy	Common Stock P-Purchase	Altman Peter President And CEO	CEO / President	26 246 Value: $50.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Altman Peter President And CEO	CEO / President	26 246 Value: $50.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Altman Peter President And CEO	CEO / President	26 246 Value: $50.0K
Apr 23, 2025 Buy	Common Stock P-Purchase	Altman Peter President And CEO	CEO / President	26 246 Value: $50.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Stertzer Simon H Director	Director	104 986 Value: $200.0K
Apr 23, 2025 Buy	Common Stock P-Purchase	Stertzer Simon H Director	Director	104 986 Value: $200.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Blank Andrew Scott Director	Director	131 233 Value: $250.0K
Apr 23, 2025 Buy	Common Stock P-Purchase	Blank Andrew Scott Director	Director	131 233 Value: $250.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Facteau Bill Director	Director	13 123 Value: $25.0K
Apr 23, 2025 Buy	Common Stock P-Purchase	Facteau Bill Director	Director	13 123 Value: $25.0K
Apr 23, 2025 Buy	Warrant (right to buy) P-Purchase	Mcclung David Chief Financial Officer	C-Suite Officer	13 123 Value: $25.0K
Apr 23, 2025 Buy	Common Stock P-Purchase	Mcclung David Chief Financial Officer	C-Suite Officer	13 123 Value: $25.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOCARDIA, INC.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture...

Read Full Profile Here